| Identification | Back Directory | [Name]
LTX-109 | [CAS]
1166254-80-3 | [Synonyms]
LTX-109
Lytixar
Voxvoganan
Lytixar(LTX-109)
L-Argininamide, L-arginyl-2,5,7-tris(1,1-dimethylethyl)-L-tryptophyl-N-(2-phenylethyl)- | [Molecular Formula]
C43H69N11O3 | [MDL Number]
MFCD30738755 | [MOL File]
1166254-80-3.mol | [Molecular Weight]
788.08 |
| Hazard Information | Back Directory | [Uses]
Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA[1][2]. | [Definition]
ChEBI: LTX-109 is a tripeptide that is the 2-phenylethyl amide of L-arginyl-2,5,7-tri-tert-butyl-L-tryptophyl-L-arginine It has a role as an antimicrobial agent and a peptidomimetic. It is a tripeptide and a monocarboxylic acid amide. | [References]
[1] Johan Isaksson, et al. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95. DOI:10.1021/jm200450h
[2] Louis D Saravolatz, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Aug;56(8):4478-82. DOI:10.1128/AAC.00194-12
[3] L D Saravolatz, et al. Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staphylococcus aureus blood isolates. Lett Appl Microbiol. 2017 Nov;65(5):410-413. DOI:10.1111/lam.12792 |
|
|